18 articles, transcripts, and reports
The patent war between Amarin (NASDAQ: AMRN) and the generic companies for cardiovascular drug Vascepa continues to be a headwind for Amarin. Shares of the…
Amarin Corporation plc (AMRN) Q1 2020 earnings call dated Apr. 30, 2020 Corporate Participants: Elisabeth Schwartz — Senior Director of Investor Relations John F. Thero — President, Chief Executive…
Shares of Amarin Corporation plc (NASDAQ: AMRN) were up 4.6% in midday trade on Tuesday, a day after the company reported preliminary results for the…
Amarin Corporation plc (AMRN) Q1 2020 earnings call dated Apr. 13, 2020 Corporate Participants: Elisabeth Schwartz — Senior Director of Investor Relations John Thero — President and Chief Executive…
Amarin Corporation plc (NASDAQ: AMRN) Q4 2019 Earnings Conference Call February 25, 2020 Corporate participants: Elisabeth Schwartz — Senior Director of Investor Relations John Thero — President and Chief…
— Amarin Corporation plc (NASDAQ: AMRN) reported earnings of $0.04 per share in the fourth-quarter 2019 vs. $0.02 per share loss expected. — Revenue grew 85% to $143.3…
Though Amarin Corporation (NASDAQ: AMRN) has been showing signs of recovery since last year, after staying low for several years, the stock has a long…
Biotech firm Amarin Corporation (NASDAQ: AMRN) had a positive start to the week, with the shares making sharp gains and hitting the highest level in…
